PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE: EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE	

CONVEYING PARTY DATA

Name	Execution Date
NEURIMMUNE THERAPEUTICS AG	10/21/2010

RECEIVING PARTY DATA

IIName:	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government	
Street Address:	NIH Division of Extramural Inventions and Technology Resources (DEITR)	
Internal Address:	6705 Rockledge Drive, Suite 310, MSC 7980	
City:	Bethesda	
State/Country:	MARYLAND	
Postal Code:	20892-7980	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	12733437

CORRESPONDENCE DATA

Fax Number: (301)480-0272

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Email: edison@nih.gov
Correspondent Name: Director, DEITR

Address Line 1: NIH, 6705 Rockledge Drive, Suite 310

Address Line 2: MSC 7980

Address Line 4: Bethesda, MARYLAND 20892-7980

NAME OF SUBMITTER: Director, DEITR

Total Attachments: 1

source=NYU-Neurimmune 12733437 License to the United States Government#page1.tif

PATENT 501361714 REEL: 025413 FRAME: 0562

License to the United States Government

Sign and submit the executed document to the appropriate funding agency (e.g. upload in iEdison).

Invention Title: Method of providing patient-specific immune response in amyloidoses and protein aggregation disorders."

Inventor(s):Karsten Henco, Roger Nitsch, Jan Grimm, Anja Zeller, Marcel Maier

U.S. Filing/Issue Date: March 1st 2010

Patent or Application Serial No.: 12/733,437

Grant/Contract Number(s): AG020245

Foreign Applications filed/intended in (countries):

The invention identified above shall be treated as a Subject Invention under **35 U.S.C. 200, et seq.**, and the Standard Patent Rights clause at **37 CFR 401.14, FAR 52.227-11** or **FAR 52.227-12** (if applicable) which are included among the terms of the above identified grant or contract award from the United State Government. This document is confirmatory of:

- 1. The nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States the invention described in any patent application and in any and all divisions, continuations, and continuations in part, and in any and all patents and re-issues granted thereon throughout the world; and
- 2. All other rights acquired by the Government by reason of the above identified grant/contract award and the laws and regulations that are applicable to award AG020245.

The Government is hereby granted an irrevocable power to inspect and make copies of the above-identified patent application.

Sign	ed this 21 day of $00000000000000000000000000000000000$	20_10
Ву	Jan Grimm	
, _	(Name of Neurimmune Official)	(Signature)
Title	CSD	
Ву_	Name of Neurimmune Official)	(Signature)
Title	COO + GEPERAL MANJAER	

For

Neurimmune Therapeutics AG

At

Wagistrasse 13 8952 Schlieren Switzerland

> PATENT REEL: 025413 FRAME: 0563

RECORDED: 11/29/2010